These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25855051)

  • 1. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
    Badat M; Kaya B; Telfer P
    Br J Haematol; 2015 Nov; 171(3):430-2. PubMed ID: 25855051
    [No Abstract]   [Full Text] [Related]  

  • 2. Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?
    Pelucchi S; Pelloni I; Arosio C; Mariani R; Piperno A
    Blood Cells Mol Dis; 2016 Mar; 57():112-4. PubMed ID: 26777753
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aceruloplasminaemia: a rare but important cause of iron overload.
    Doyle A; Rusli F; Bhathal P
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
    Galanello R; Kattamis A; Piga A; Fischer R; Leoni G; Ladis V; Voi V; Lund U; Tricta F
    Haematologica; 2006 Sep; 91(9):1241-3. PubMed ID: 16956824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iron chelators.
    Kwiatkowski JL
    Pediatr Clin North Am; 2008 Apr; 55(2):461-82, x. PubMed ID: 18381096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.
    Mariani R; Arosio C; Pelucchi S; Grisoli M; Piga A; Trombini P; Piperno A
    Gut; 2004 May; 53(5):756-8. PubMed ID: 15082597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Loukopoulos D
    Haematologica; 2005 Oct; 90(10):1304-5. PubMed ID: 16219564
    [No Abstract]   [Full Text] [Related]  

  • 15. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
    Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
    Calder GL; Lee MH; Sachithanandan N; Bell S; Zeimer H; MacIsaac RJ
    Intern Med J; 2017 Jan; 47(1):115-118. PubMed ID: 28076908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
    Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.